Clinuvel Pharmaceuticals Stock Forecast, Price & News

Clinuvel Pharmaceuticals (ASX:CUV) Frequently Asked Questions

What stocks does MarketBeat like better than Clinuvel Pharmaceuticals?

Wall Street analysts have given Clinuvel Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clinuvel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals declared a Interim dividend on Friday, August 27th. Stockholders of record on Thursday, September 16th will be paid a dividend of 0.025 per share on Thursday, September 16th. This represents a dividend yield of 0.07%. The ex-dividend date of this dividend is Wednesday, September 1st.
View Clinuvel Pharmaceuticals' dividend history.

Is Clinuvel Pharmaceuticals a good dividend stock?

Clinuvel Pharmaceuticals pays an annual dividend of A$0.03 per share and currently has a dividend yield of 0.06%. The dividend payout ratio of Clinuvel Pharmaceuticals is 6.20%. This payout ratio is at a healthy, sustainable level, below 75%.
View Clinuvel Pharmaceuticals' dividend history.

Who are Clinuvel Pharmaceuticals' key executives?

Clinuvel Pharmaceuticals' management team includes the following people:

• Dr. Philippe Jacques Wolgen M.B.A., MBA, M.D., CEO, MD & Director (Age 58, Pay $1.73M)
• Mr. Darren M. Keamy, CFO & Company Sec. (Age 48, Pay $372.08k)
• Dr. Dennis J. Wright, Chief Scientific Officer
• Mr. Malcolm Bull, Head of Investor Relations
• Lachlan Hay, Gen. Mang. of Europe

Who are some of Clinuvel Pharmaceuticals' key competitors?

Some companies that are related to Clinuvel Pharmaceuticals include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of CUV's competitors.

What other stocks do shareholders of Clinuvel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals investors own include Zynga (ZNGA), Worldpay (WP), VolitionRx (VNRX), REA Group (REA), CSL (CSL), Cochlear (COH), (CATB) and Afterpay (APT).

What is Clinuvel Pharmaceuticals' stock symbol?

Clinuvel Pharmaceuticals trades on the ASX under the ticker symbol "CUV."

How much money does Clinuvel Pharmaceuticals make?

Clinuvel Pharmaceuticals has a market capitalization of $0.00 and generates $47.98 million in revenue each year.

What is Clinuvel Pharmaceuticals' official website?

The official website for Clinuvel Pharmaceuticals is www.clinuvel.com.

How can I contact Clinuvel Pharmaceuticals?

The company can be reached via phone at 61 3 9660 4900.